4DMedical raises (ASX:4DX) $150m to fuel U.S. lung imaging push and expand AI respiratory portfolio

4DMedical Limited, listed on the Australian Securities Exchange under the ticker ASX:4DX, has secured firm commitments for an AUD $150 million institutional placement priced at AUD $3.80 per share. The capital raise introduces a set of new global long-only institutional investors to the company’s register while also receiving strong participation from existing shareholders. As a result, 4DMedical now holds a pro forma cash position of over AUD $200 million, a financial base that management believes will enable it to accelerate commercial execution of its flagship CT:VQ platform in the United States and fund its broader strategy through to profitability.

The placement was executed with less than 4 percent dilution to existing shareholders, a structural advantage enabled by recycling shares previously issued to Alpha Investment Partners as part of a funding facility disclosed in June 2024. These shares, although technically pre-issued, were repurposed as part of the offering, and all associated funds from their sale will flow directly to 4DMedical for commercial and research execution. This hybrid placement-block trade structure reflects a balance sheet-conscious approach by 4DMedical management and positions the company for near-term clinical growth without compromising shareholder equity integrity.

What does 4DMedical intend to achieve with its AUD $150 million capital raise?

The company has outlined a targeted use of proceeds focused on five operational priorities. First, the capital will significantly scale sales, marketing, and business development functions in the United States. This includes the expansion of go-to-market teams capable of navigating complex academic and system-level procurement channels, particularly given the early adoption of CT:VQ by elite institutions such as Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health.

Second, 4DMedical is prioritising customer success infrastructure to ensure smooth clinical deployment and workflow integration. As more hospitals adopt CT:VQ, the company needs to address IT, radiology, and pulmonology alignment, a common barrier in software-as-a-medical-device rollouts. A well-resourced support infrastructure can shorten time-to-value and help convert pilot deployments into system-wide adoption.

Third, funds are earmarked for research and development to maintain technical leadership in functional imaging. The company’s existing platform includes CT:VQ, CT LVAS, and XV LVAS, all of which are delivered via a Software-as-a-Service model. The integration of artificial intelligence from the 2023 acquisition of Imbio has expanded analytical capabilities and allows the company to refine precision metrics for clinical decision-making. R&D will likely focus on adjacent applications beyond ventilation and perfusion, potentially including fibrotic lung diseases, COVID-related sequelae, and surgical planning.

Fourth, a portion of the proceeds will provide working capital and administrative coverage, giving 4DMedical flexibility to support broader corporate functions, including regulatory, legal, and investor relations. Lastly, the company has explicitly stated that the strengthened cash position gives it strategic optionality for inorganic growth, should synergistic opportunities arise in the pulmonary or imaging data ecosystem.

How did 4DMedical structure the institutional placement to limit dilution risk?

4DMedical took an unconventional but shareholder-friendly approach in structuring the AUD $150 million placement. Rather than issuing the full amount in new shares, the company divided the raise into a AUD $79.1 million fresh placement and a AUD $70.9 million block trade using shares previously issued to Alpha Investment Partners. These shares were originally allocated as part of a secured funding facility but were not in public float. By repurposing them for the institutional raise, 4DMedical limited the effective dilution to just under 3.9 percent, well below sector norms for a transaction of this size.

The AUD $3.80 issue price represented an 11.4 percent discount to the last traded price but was within acceptable bounds given the institutional profile of the buyers and the scale of the raise. Settlement of the placement and block trade is scheduled for January 21 and 23 respectively, with shares commencing trading on January 22. The repurposing of Alpha’s shares ensures that all proceeds from both the primary and secondary components of the transaction will be directed to 4DMedical for operational use, with no payout to Alpha Investment Partners.

This structural efficiency was likely a key factor in attracting high-quality institutional capital, particularly in a healthcare technology sector where public raises can be punitive to long-term equity value. The company’s ability to leverage pre-existing capital instruments while optimising inflow efficiency sets a precedent for future medtech placements in the Australian market.

What does management’s option exercise indicate about long-term confidence?

The timing of the raise was also accompanied by insider option exercises by both Managing Director and Chief Executive Officer Dr Andreas Fouras and Executive Director and Chief Financial Officer Julian Sutton. Dr Fouras exercised 1.85 million options, partially funded by the sale of 263,157 shares at the placement price. Mr Sutton exercised 4.27 million options, fully funding his conversion via the sale of 2.27 million shares.

Following these exercises, Dr Fouras will hold approximately 66.4 million shares, equating to 11.9 percent of the company’s total share count, while Mr Sutton will hold roughly 2.5 million shares, representing 0.5 percent ownership. Notably, both executives increased their absolute shareholdings as a result of the placement, with Fouras adding over 1.58 million shares and Sutton acquiring a net gain of 2 million shares.

Importantly, both directors have committed to not selling any additional shares during calendar year 2026. The combined option exercise injected approximately AUD $6.9 million into the company’s cash reserves, further strengthening its liquidity profile. Insider participation during a capital raise is generally interpreted as a strong conviction signal, and this instance was no exception. Investors are likely to view the alignment between management and shareholder outcomes as a positive indicator of near-term execution confidence.

How is the CT:VQ platform progressing in U.S. academic health systems?

CT:VQ is already deployed at four leading U.S. academic medical centres less than four months after FDA clearance. The institutions—Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health—represent a strategically curated cohort of high-visibility validation sites. These are not only among the most respected names in respiratory and radiology research but also serve as referral anchors and technology opinion leaders across the U.S. health system.

The technology itself provides ventilation and perfusion insights from conventional CT imaging, eliminating the need for nuclear tracers or invasive procedures. By leveraging advanced image processing and AI, CT:VQ delivers quantitative and dynamic visualisations of pulmonary function in real time. This capability has the potential to replace legacy VQ scanning and even challenge aspects of traditional pulmonary function testing in pre-surgical assessments, chronic lung disease management, and acute diagnostic settings.

Adoption at these anchor institutions is likely to form the backbone of 4DMedical’s broader U.S. go-to-market strategy. The validation gained from early deployments should facilitate procurement traction across integrated delivery networks and major hospital systems. The company’s partnership with Philips, announced in late 2025, may also serve as a multiplier if distribution or software bundling opportunities are executed effectively. Philips’ established footprint in diagnostic imaging provides a logical integration pathway, though no further terms have yet been disclosed.

What execution risks remain for 4DMedical in achieving profitability?

Despite the strength of the current placement and its near-term institutional backing, 4DMedical faces a number of execution risks. First is the challenge of scaling from academic early adopters to large-scale commercial penetration within U.S. hospital networks. Selling into complex, payer-aligned systems requires not only strong clinical validation but also clear health economic outcomes, which will need to be documented through real-world use and health technology assessments.

Second, the imaging AI sector remains competitive, with players such as HeartFlow, Aidoc, and Arterys also pushing advanced, non-invasive diagnostics across various anatomical domains. While 4DMedical has a first-mover advantage in functional respiratory imaging, it must maintain this lead through product innovation and operational consistency. Regulatory hurdles, reimbursement coding, and EHR integration complexity remain material barriers to scale.

Finally, any delay in commercial conversion or customer adoption could push out the company’s profitability timeline, even with more than AUD $200 million in cash on hand. Market expectations will likely pivot by late 2026 or early 2027 toward evidence of sustainable SaaS revenue growth, with higher scrutiny on churn, average revenue per site, and cohort retention metrics.

Key takeaways on what this AUD $150 million capital raise means for 4DMedical, its competitors, and the imaging AI sector

• 4DMedical has completed an AUD $150 million institutional placement at AUD $3.80 per share, introducing global long-only investors while limiting dilution to under 4 percent.
• The capital will fund U.S. commercial scale-up, advanced customer support, and expansion of its AI-driven imaging product portfolio.
• The placement was structured with a hybrid block trade and primary issue format, enabling 4DMedical to redirect funds from pre-issued shares originally allocated to Alpha Investment Partners.
• Chief Executive Officer Andreas Fouras and Chief Financial Officer Julian Sutton exercised options during the placement, increasing their shareholdings and injecting AUD $6.9 million into the company.
• CT:VQ has achieved early deployment at major U.S. academic centres and is positioned to challenge legacy pulmonary imaging modalities.
• A strategic partnership with Philips could amplify distribution scale, although execution timelines and integration terms remain undisclosed.
• With over AUD $200 million in cash reserves, 4DMedical has a clear runway to target profitability and deeper institutional penetration in the U.S. market.
• Risks include procurement cycle delays, competition from other imaging AI platforms, and the need to prove economic value to large health systems.